Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Looking Into Precision BioSciences, Inc. – Common Stock’s Return On Capital Employed
Benzinga Pro data, Precision BioSciences, Inc. - Common Stock (NASDAQ:DTIL) reported Q2 sales of $3.82 million. Earnings fell to a loss of $31.04 million, resulting in a 10.18% decrease from last quarter. Precision BioSciences, Inc.
This Healthcare Stock Jumps Around 188%, Here’s 83 Biggest Movers From Yesterday
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers
Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
40 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma’s Alzheimer’s Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours:
21 Stocks Moving in Wednesday’s Pre-Market Session: Revlon, La-Z-Boy, Houston American, Ovintiv And More
Gainers
Codex DNA, Inc. (NASDAQ: DNAY) rose 64.5% to $3.52 in pre-market trading after declining 10% on Tuesday.
US Stock Futures Down; Powell Testimony In Focus
Pre-open movers
U.S. stock futures traded lower in early pre-market trade after the Dow Jones gained more than 600 points in the previous session.
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
- Precision to Receive $75